Johnson & Johnson (NYSE:JNJ) Shares Purchased by Rogco LP

Rogco LP boosted its stake in Johnson & Johnson (NYSE:JNJ) by 1.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 10,792 shares of the company’s stock after purchasing an additional 131 shares during the period. Johnson & Johnson comprises approximately 0.6% of Rogco LP’s portfolio, making the stock its 27th largest position. Rogco LP’s holdings in Johnson & Johnson were worth $1,561,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in JNJ. IFS Advisors LLC increased its holdings in Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after purchasing an additional 100 shares during the last quarter. Highline Wealth Partners LLC purchased a new position in Johnson & Johnson in the 3rd quarter valued at approximately $31,000. Bay Harbor Wealth Management LLC purchased a new position in Johnson & Johnson in the 4th quarter valued at approximately $32,000. RPg Family Wealth Advisory LLC purchased a new position in Johnson & Johnson in the 3rd quarter valued at approximately $35,000. Finally, Mowery & Schoenfeld Wealth Management LLC boosted its position in Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after buying an additional 91 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, Director Mark A. Weinberger purchased 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ? increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Price Performance

Shares of JNJ opened at $157.93 on Thursday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The stock has a market cap of $380.23 billion, a PE ratio of 23.75, a price-to-earnings-growth ratio of 2.50 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a fifty day moving average price of $148.34 and a 200 day moving average price of $155.86.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the business posted $2.29 earnings per share. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.14%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Analysts Set New Price Targets

Several brokerages have commented on JNJ. Morgan Stanley decreased their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Leerink Partners decreased their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Citigroup decreased their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Finally, Stifel Nicolaus decreased their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.